Recurrent Pancreatic Carcinoma Active Not Recruiting Phase 1 Trials for Durvalumab (DB11714)

Also known as: Pancreatic carcinoma recurrent / Pancreas carcinoma recurrent / Pancreatic cancer recurrent

IndicationStatusPhase
DBCOND0043478 (Recurrent Pancreatic Carcinoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03257761Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerTreatment